EP2413696A4 - Compositions for treatment of alzheimer's disease - Google Patents

Compositions for treatment of alzheimer's disease

Info

Publication number: EP2413696A4
Authority: EP; European Patent Office
Prior art keywords: alzheimer; disease; compositions; treatment
Prior art date: 2009-04-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP10759174A

Other languages

German (de)

French (fr)

Other versions

EP2413696A1 (en

Inventor

Jorge Galvez

Javier Llompart

David Land

Giulio Pasinetti

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Icahn School of Medicine at Mount Sinai

Medisyn Technologies Inc

Original Assignee

Medisyn Technologies Inc

Mount Sinai School of Medicine

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-03

Filing date

2010-04-05

Publication date

2012-10-24

2010-04-05 Application filed by Medisyn Technologies Inc, Mount Sinai School of Medicine filed Critical Medisyn Technologies Inc

2012-02-08 Publication of EP2413696A1 publication Critical patent/EP2413696A1/en

2012-10-24 Publication of EP2413696A4 publication Critical patent/EP2413696A4/en

Status Withdrawn legal-status Critical Current

Links

208000024827 Alzheimer disease Diseases 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP10759174A 2009-04-03 2010-04-05 Compositions for treatment of alzheimer's disease Withdrawn EP2413696A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US21182109P	2009-04-03	2009-04-03
PCT/US2010/001041 WO2010114636A1 (en)	2009-04-03	2010-04-05	Compositions for treatment of alzheimer's disease

Publications (2)

Publication Number	Publication Date
EP2413696A1 EP2413696A1 (en)	2012-02-08
EP2413696A4 true EP2413696A4 (en)	2012-10-24

Family

ID=42828621

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP10759174A Withdrawn EP2413696A4 (en)	2009-04-03	2010-04-05	Compositions for treatment of alzheimer's disease

Country Status (4)

Country	Link
EP (1)	EP2413696A4 (en)
AU (1)	AU2010232923A1 (en)
CA (1)	CA2759187A1 (en)
WO (1)	WO2010114636A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2012281019B2 (en) *	2011-07-13	2016-05-12	Microbiotix, Inc.	Inhibitors of bacterial type III secretion system
CN102391262A (en) *	2011-07-20	2012-03-28	延边大学	Antimicrobial compound containing 3-carboxyalkyl rhodanine derivative
US9783550B2 (en)	2013-05-14	2017-10-10	The Board Of Regents Of The University Of Texas System	Highly potent inhibitors of porcupine
WO2022120150A1 (en) *	2020-12-03	2022-06-09	Duke University	Amiloride derivatives and methods of using same for the treatment of viral infections

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992001455A1 (en) *	1990-07-25	1992-02-06	Luedke Hans Werner	Medicament against degenerative brain performance diseases of the alzheimer type and cholinergic system disturbances
WO2003070737A1 (en) *	2002-02-21	2003-08-28	Polimeri Europa S.P.A.	Nickel tris-pyrazolyl borate complexes and their use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0335979A4 (en) *	1987-09-16	1992-02-26	Taiho Pharmaceutical Company, Limited	Thienopyrimidine derivatives
EP0361489A3 (en) *	1988-09-30	1991-06-12	Chugai Seiyaku Kabushiki Kaisha	Novel 3,4-diaminoquinoline and pyridine compounds
EP0915090A1 (en) *	1992-09-10	1999-05-12	Eli Lilly And Company	Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
WO1995027693A1 (en) *	1994-04-06	1995-10-19	Shionogi & Co., Ltd.	α-SUBSTITUTED PHENYLACETIC ACID DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND AGRICULTURAL BACTERICIDE CONTAINING THE SAME
DE19548146C1 (en) *	1995-12-21	1997-11-20	Basf Ag	Tris (pyrazolyl) borate metal complex catalysts and their use
WO1999024420A1 (en) *	1997-11-06	1999-05-20	Smithkline Beecham Plc	Pyrimidinone compounds and pharmaceutical compositions containing them
US6559155B1 (en) *	1998-08-21	2003-05-06	Smithkline Beecham P.L.C.	Pyrimidinone derivatives for the treatment of atherosclerosis
JP2004532234A (en) *	2001-04-27	2004-10-21	バーテックス　ファーマシューティカルズ　インコーポレイテッド	Triazole-derived kinase inhibitors and uses thereof
TW200303742A (en) *	2001-11-21	2003-09-16	Novartis Ag	Organic compounds
DE10217006A1 (en) *	2002-04-16	2003-11-06	Merck Patent Gmbh	Substituted indoles
JP2007500128A (en) *	2003-07-25	2007-01-11	アムジエン・インコーポレーテツド	Substituted heterocyclic compounds and methods of use
CA2563963A1 (en) *	2004-04-28	2005-11-10	Pfizer Inc.	3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
WO2006047254A1 (en) *	2004-10-22	2006-05-04	Regents Of The University Of Minnesota	Assemblies of oligomeric amyloid beta protein and uses thereof
US7718683B2 (en) *	2006-07-14	2010-05-18	Chemocentryx, Inc.	Triazolyl phenyl benzenesulfonamides
WO2008128982A1 (en) *	2007-04-18	2008-10-30	Probiodrug Ag	Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors
EP2193117A1 (en) *	2007-07-16	2010-06-09	Wyeth a Corporation of the State of Delaware	Inhibitors of beta amyloid production

2010
- 2010-04-05 WO PCT/US2010/001041 patent/WO2010114636A1/en not_active Ceased
- 2010-04-05 AU AU2010232923A patent/AU2010232923A1/en not_active Abandoned
- 2010-04-05 CA CA2759187A patent/CA2759187A1/en not_active Abandoned
- 2010-04-05 EP EP10759174A patent/EP2413696A4/en not_active Withdrawn

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992001455A1 (en) *	1990-07-25	1992-02-06	Luedke Hans Werner	Medicament against degenerative brain performance diseases of the alzheimer type and cholinergic system disturbances
WO2003070737A1 (en) *	2002-02-21	2003-08-28	Polimeri Europa S.P.A.	Nickel tris-pyrazolyl borate complexes and their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010114636A1 *

Also Published As

Publication number	Publication date
CA2759187A1 (en)	2010-10-07
EP2413696A1 (en)	2012-02-08
AU2010232923A1 (en)	2011-11-03
WO2010114636A1 (en)	2010-10-07

Legal Events

Date	Code	Title	Description
2012-01-06	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2012-02-08	17P	Request for examination filed	Effective date: 20111102
2012-02-08	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
2012-02-22	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: MOUNT SINAI SCHOOL OF MEDICINE Owner name: MEDISYN TECHNOLOGIES, INC.
2012-07-11	DAX	Request for extension of the european patent (deleted)
2012-10-24	A4	Supplementary search report drawn up and despatched	Effective date: 20120926
2012-10-24	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/69 20060101ALI20120920BHEP Ipc: A61P 25/28 20060101ALI20120920BHEP Ipc: A61K 31/415 20060101ALI20120920BHEP Ipc: A61K 31/4709 20060101ALI20120920BHEP Ipc: A61K 31/513 20060101ALI20120920BHEP Ipc: A01N 43/64 20060101AFI20120920BHEP Ipc: A61K 31/426 20060101ALI20120920BHEP Ipc: A61K 31/4196 20060101ALI20120920BHEP Ipc: A61K 31/404 20060101ALI20120920BHEP
2013-10-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2013-11-20	18D	Application deemed to be withdrawn	Effective date: 20130426

Publication	Publication Date	Title
IL264736B (en)	2020-05-31	Compositions comprising zonisamide for use in the treatment of alzheimer's disease related disorders
ZA201100034B (en)	2012-04-25	Pharmaceutical compositions for treatment of parkinson's disease
EP2151435A4 (en)	2011-09-14	Pharmaceutical composition for treatment of alzheimer's disease
EP2382176A4 (en)	2015-09-09	Use of nitrogen-containing curcumin analogs for the treatment alzheimer's disease
ZA201006868B (en)	2012-03-28	Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
IL213259A0 (en)	2011-07-31	Composition for the use to treat alzheimer's disease
IL216399A0 (en)	2012-01-31	Pharmaceutical composition for the treatment of heart diseases
EP2273880A4 (en)	2013-06-19	Novel formulations for treatment of migraine
IL230335A (en)	2015-07-30	Composition for treatment of cartilage disease
EP2707369A4 (en)	2014-12-10	Compositions and methods for treating alzheimer's disease
PL3064206T3 (en)	2020-02-28	Treatment of huntington's disease using laquinimod
EP2485733A4 (en)	2014-06-18	Methods for treating alzheimer's disease
PL2429507T3 (en)	2018-01-31	Phosphate-free pharmaceutical composition for the treatment of glaucoma
SG11201403272YA (en)	2014-08-28	Compositions and methods for treating alzheimer's disease
EP2320939A4 (en)	2012-09-12	Tissue kallikrein for the treatment of parkinson's disease
EP2421554A4 (en)	2012-11-28	Tissue kallikrein for the treatment of huntington's disease
EP2413696A4 (en)	2012-10-24	Compositions for treatment of alzheimer's disease
EP2391379A4 (en)	2012-11-28	Compound and method for treatment of alzheimer's disease
IL217149A0 (en)	2012-02-29	Compositions and methods for treating parkinson's disease
HU0900231D0 (en)	2009-06-29	Compositions for the treatment of allergic disorders
GB0811555D0 (en)	2008-07-30	Treatment of Alzheimer's disease
IL214340A0 (en)	2011-09-27	Methods and compositions for treating alzheimer's disease
IL209804A0 (en)	2011-02-28	Pharmaceutical compositions for treatment of parkinson's disease
GB0913357D0 (en)	2009-09-16	Diagnosis of alzheimer's disease
GB0911539D0 (en)	2009-08-12	Diagnosis of alzheimer's disease